Semin Arthritis Rheu: Characteristics of COVID-19 infection in patients with influenzae treatment with immunosuppressants

The purpose of this study was to analyze the clinical characteristics and prognosis ofinfection in patients treated withimmuno
inhibitorscoVID-19studied a range of RD patients who treated and contracted COVID-19 with disease-improving anti-rheumatic drugs (DMARDs) through a retrospective medical records reviewThe literature search identified nine similar single-case and case series studies and was also included in the studythe author's hospital had 4 RD inpatients infected with COVID-19, with an average age of 57 to 21 years2 patients with mild infection, 2 patients with severe COVID-19-related respiratory complications, of which 1 patient using Sukinsazumab required mechanical ventilation, and 1 patient with rituximatomaina developed viral pneumonia that required oxygenationAcute stage responders were elevated in 4 patients, lymphocytes decreased in 2 patients with mild COVID-19, and 2 patients with severe COVID-19 had normal lymphocyte count, while IL-6 levels were elevatedNo patients experienced RD deteriorationIn the literature, nine COVID-19 studies included 197 patients with various inflammatory RDpatientsMost patients use DMARDs or biologics, the most common of which is TNF alpha inhibitors2 patients treated with tobead monobresistance were mildly infectedOf the 2 patients treated with rituximab, 1 was severe COVID-19 that required mechanical ventilationOf the 6 patients treated with Sukin suprem, 1 was hospitalized Of the 201 cases, 12 were fatal, with an estimated mortality rate of 5.9% RD patients were susceptible to COVID-19 Different DMARDs or biologics affect the process of viral infection to varying degrees Patients who use hydroxychloroquine, TNF alpha antagonists, or toluzumab are less likely Rituximab or sukinsone virus infection may worsen Further research is needed